CRISPR/Cas9 from bench to bedside: what clinicians need to know before application?

In October 2020, Dr. Emmanuelle Charpentier and Dr. Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering work in precise genome editing using the CRISPR technology. Although CRISPR technology has developed rapidly in the last decade, there are still many uncertainties before eventua...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zi-Qing, Li, Chao-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722470/
https://www.ncbi.nlm.nih.gov/pubmed/33287895
http://dx.doi.org/10.1186/s40779-020-00292-2
_version_ 1783620160808026112
author Li, Zi-Qing
Li, Chao-Hong
author_facet Li, Zi-Qing
Li, Chao-Hong
author_sort Li, Zi-Qing
collection PubMed
description In October 2020, Dr. Emmanuelle Charpentier and Dr. Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering work in precise genome editing using the CRISPR technology. Although CRISPR technology has developed rapidly in the last decade, there are still many uncertainties before eventual use in clinical settings. In this mini review, we summarize the current efforts in addressing the limitations of CRISPR technology and future directions.
format Online
Article
Text
id pubmed-7722470
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77224702020-12-08 CRISPR/Cas9 from bench to bedside: what clinicians need to know before application? Li, Zi-Qing Li, Chao-Hong Mil Med Res Letter to the Editor In October 2020, Dr. Emmanuelle Charpentier and Dr. Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering work in precise genome editing using the CRISPR technology. Although CRISPR technology has developed rapidly in the last decade, there are still many uncertainties before eventual use in clinical settings. In this mini review, we summarize the current efforts in addressing the limitations of CRISPR technology and future directions. BioMed Central 2020-12-08 /pmc/articles/PMC7722470/ /pubmed/33287895 http://dx.doi.org/10.1186/s40779-020-00292-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter to the Editor
Li, Zi-Qing
Li, Chao-Hong
CRISPR/Cas9 from bench to bedside: what clinicians need to know before application?
title CRISPR/Cas9 from bench to bedside: what clinicians need to know before application?
title_full CRISPR/Cas9 from bench to bedside: what clinicians need to know before application?
title_fullStr CRISPR/Cas9 from bench to bedside: what clinicians need to know before application?
title_full_unstemmed CRISPR/Cas9 from bench to bedside: what clinicians need to know before application?
title_short CRISPR/Cas9 from bench to bedside: what clinicians need to know before application?
title_sort crispr/cas9 from bench to bedside: what clinicians need to know before application?
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722470/
https://www.ncbi.nlm.nih.gov/pubmed/33287895
http://dx.doi.org/10.1186/s40779-020-00292-2
work_keys_str_mv AT liziqing crisprcas9frombenchtobedsidewhatcliniciansneedtoknowbeforeapplication
AT lichaohong crisprcas9frombenchtobedsidewhatcliniciansneedtoknowbeforeapplication

Ejemplares similares